FGL2 was previously shown by our group to be involved in the malignant transformation of low- to high-grade gliomas and is expressed in other cancers, such as HCC, prostate, B cell lymphoma, colorectal, and lung cancers (7). Here, FGL2 is linked to central nervous system cancer.